Activity of telavancin against complicated skin and skin structure infection isolates according to specimen source

Abstract number: P536

Benton B.M., Barriere S.L., Kitt M.M., Krause K.M.

Objective: Telavancin (TLV) is a novel, bactericidal lipoglycopeptide with a broad and potent Gram-positive spectrum of activity. TLV's unique, multifunctional mechanism of action includes inhibition of bacterial cell wall biosynthesis and disruption of bacterial membrane function. The efficacy and safety of TLV were studied in patients with complicated skin and skin structure infections (cSSSIs) in two identical, worldwide, Phase 3 studies (ATLAS 1 and ATLAS 2). Here, we report the susceptibility testing results by infection type (major abscess, deep/extensive cellulitis, wound, burn or ulcer) for TLV against the Gram-positive isolates collected in these studies.

Methods: A total of 1506 baseline Gram-positive isolates were obtained from among the 1867 cSSSI patients enrolled in the ATLAS studies throughout North America, Europe, South Africa, South America and Asia during 2005–06. All isolates were identified and susceptibility tests were performed at a central laboratory. MIC values were determined by the CLSI broth microdilution method, using frozen reference MIC panels.

Results: See Table.

Conclusions: TLV was active against Gram-positive pathogens common in cSSSIs, irrespective of the infection site. These data highlight the potential therapeutic use of TLV in the treatment of Gram-positive cSSSIs at a variety of infection sites.